BioPharma Dive Jan 5, 2026 Zenas shares crash after top drug misses expectations in immune disease study
FierceBiotech Jan 5, 2026 Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
FierceBiotech Jan 5, 2026 Abbott launches AI-based Libre Assist, its new in-app feature for meal planning
Thermo Fisher Jan 5, 2026 Will Thermo Fisher’s Pharma Demand Outlook and Clario Deal Reframe Its Investment Story (TMO)? - Yahoo Finance